Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury

Coronary Artery Disease

Volumn 22, Issue 2, 2011, Pages 87-91

  Yu, Xing Long ^a   Zhang, Hai Juan ^a   Ren, Shao Da ^a   Geng, Jing ^a   Wu, Ting Ting ^a   Chen, Wen Qiang ^a   Ji, Xiao Ping ^a   Zhong, Lin ^a   Ge, Zhi Ming ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Atorvastatin; Inflammatory reaction; Myocardial injury percutaneous coronary intervention

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE; TROPONIN T;

ADULT; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; INFLAMMATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE COMPLICATION; PRIORITY JOURNAL;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CHINA; CREATINE KINASE, MB FORM; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; PYRROLES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I;

EID: 79955007482     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328341baee     Document Type: Article

References (18)

1. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-948. (Pubitemid 47393576)
2. Jones PH, Famer JA. Adjunctive interventions in myocardial infarction: the role of statin therapy. Curr Atheroscler Rep 2008;10:142-148. (Pubitemid 351486149)
3. Chen YC, Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, et al. Pharmacogenetic study of statin therpy and cholesterol reduction. JAMA 2004;291:2821-2827. (Pubitemid 38747801)
4. Wassmann S, Faul A, Hennen B, Scheuer B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res 2003;93: e98-e103.
5. Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, Tesauro M. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005;111:412-419. (Pubitemid 40204424)
6. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein mediated monocyte chemoattractant protein-1 induction in human endothelial cells by antiatherosclerosis drugs. Circulation 2001;103:2531-2534. (Pubitemid 32521959)
7. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:39-43.
8. Yildiz A, Cakar MA, Baskurt M, Okcun B, Guzelsoy D, Coskun U. The effects of atorvastatin therapy on endothelial function in patients with coronary artery disease. Cardiovasc Ultrasound 2007;30:5-51.
9. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol 1991;17:621-626.
10. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-1536. (Pubitemid 26320254)
11. Brener SJ, Ellis SG, Schneider J, Topoi EJ. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 2002;23:869-876. (Pubitemid 34717422)
12. Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coll Cardiol 2003;42:1412-1414. (Pubitemid 37267282)
13. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565. (Pubitemid 35315836)
14. Razzouk L, Muntner P, Bansilal S, Kini AS, Aueja A, Mozes J, Ivan O. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. Am Heart J 2009;158:277-283.
15. Fesmire FM, Christenson RH, Fody EP, Feintuch TA. D creatine kinase-MB outperforms myoglobin at two hours during the emergency department identification and exclusion of troponin positive non-ST segment elevation acute coronary syndromes. Ann Emerg Med 2004;44:9-12.
16. Hara H, Nakamura M, Yokouch I, Kimura K, Nemoto N, Itos S, Ono T. Aggressive statin therapy in multicenter and effectiveness for the reduction of intramyocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study. Ther Adv Cardiovasc Dis 2009;3:357-365.
17. La Rosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435. (Pubitemid 40471450)
18. Pedersen TR, Faergeman O, Kastelein JJ, Oisson AG, Tikkanen MJ, Hoime I, Larsen ML. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized placebo led trial. JAMA 2005;294:2437-2445. (Pubitemid 41627921)